| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99233 |
Prolong inpt eval add15 m |
3,683 |
1,147 |
$157K |
| 99309 |
Subsequent nursing facility care, per day, low to moderate complexity |
9,582 |
4,564 |
$154K |
| 99223 |
Prolong inpt eval add15 m |
1,497 |
1,270 |
$120K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
8,706 |
6,634 |
$70K |
| 99310 |
Prolong nursin fac eval 15m |
1,564 |
1,048 |
$40K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
3,970 |
3,046 |
$31K |
| 99232 |
Subsequent hospital care, per day, moderate complexity |
920 |
319 |
$25K |
| 99306 |
Prolong nursin fac eval 15m |
590 |
467 |
$24K |
| 99308 |
Subsequent nursing facility care, per day, straightforward |
1,306 |
708 |
$16K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
599 |
551 |
$14K |
| G3002 |
Chronic pain management and treatment, monthly bundle including, diagnosis; assessment and monitoring; administration of a validated pain rating scale or tool; the development, implementation, revision, and/or maintenance of a person-centered care plan that includes strengths, goals, clinical needs, and desired outcomes; overall treatment management; facilitation and coordination of any necessary behavioral health treatment; medication management; pain and health literacy counseling; any necessary chronic pain related crisis care; and ongoing communication and care coordination between relevant practitioners furnishing care, e.g. physical therapy and occupational therapy, complementary and integrative approaches, and community-based care, as appropriate. required initial face-to-face visit at least 30 minutes provided by a physician or other qualified health professional; first 30 minutes personally provided by physician or other qualified health care professional, per calendar month. (when using g3002, 30 minutes must be met or exceeded.) |
3,455 |
2,877 |
$6K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
46 |
44 |
$3K |
| 99305 |
|
57 |
45 |
$2K |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
1,881 |
1,159 |
$732.91 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
701 |
517 |
$353.55 |
| 96132 |
|
29 |
29 |
$293.27 |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
558 |
405 |
$125.72 |
| G3003 |
Each additional 15 minutes of chronic pain management and treatment by a physician or other qualified health care professional, per calendar month. (list separately in addition to code for g3002. when using g3003, 15 minutes must be met or exceeded.) |
3,403 |
1,618 |
$36.73 |
| G9903 |
Patient screened for tobacco use and identified as a tobacco non-user |
2,166 |
958 |
$0.03 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
4,688 |
2,154 |
$0.02 |
| 4044F |
|
990 |
495 |
$0.00 |
| G2148 |
Multimodal pain management was used |
3,350 |
1,464 |
$0.00 |
| G9902 |
Patient screened for tobacco use and identified as a tobacco user |
618 |
300 |
$0.00 |
| 1123F |
|
3,004 |
1,357 |
$0.00 |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
19 |
15 |
$0.00 |
| 1124F |
|
33 |
20 |
$0.00 |
| G8404 |
Lower extremity neurological exam performed and documented |
3,217 |
1,394 |
$0.00 |